





Ruth Evans, OD Manager - Scientific and Clinical NHSBT Filton





Why do we separate whole blood into different components?





Whole Blood Pack Type

- Identified at donor session
- Determines components that can be produced:
 - 1. Whole Blood Filtration (Top and Top)
 - (red blood cells, plasma or cryoprecipitate)
 - 2. Bottom and Top
 - (red blood cells, and platelets; rarelyplasma and cryoprecipitate)





Whole Blood Filter (WBF) Pack







Overnight storage

- Regardless of bleed type most WB is stored overnight before processing
 - Phagocytes in product engulf bacteria















Leucodepletion of Whole Blood Donations









Centrifugation - fast (3800 rpm)



















SAG-M additive solution added

Red Cells 4℃ +/- 2 35 days



















Fresh Frozen Plasma (FFP)

< -25℃ 3 years





Bottom and Top (BAT) Pack















Plasma

Buffy Coat (for platelets)

Red Cells







Scientific and clinical Leucodepletion of Red Cells



NHS

Blood and Transplant







Scientific and clinical Blood and Transplant



- 4 BCs + 1 PAS
- Same ABO group
- Rh and CMV only neg if all neg
- Unique pool number generated

SCIENTIFIC AND CLINICAL SCIENTIFIC AND CLINICAL DEVELOPMENT Platelet Pooling Slood and Transplant - Sterile Connecting Device (SCD)



Scientific and clinical Platelet Pooling SCIENTIFIC AND CLINICAL - SCD





OTERUMO TERUMO

Sterile Connection
Joins tubing aseptically
Disposable copper blade
Creates a 'train'









PAS is washed through the "train" of bags to pool together the contents of the 4 Buffy coat bags into the terminal bag

















NHS Blood and Transplant

Pooled Platelet 22°C +/-2 gently agitating 7 days (if bacterial monitoring)

Scientific and clinical Special components: Cryoprecipitate











Granulocytes





Stored 22°C without agitation for 24 hours only

Must contain >5x10⁹ cells per unit

Must be CMV neg (if patient CMV neg)



Donation Testing – Grouping



- Mandatory testing:
 - ABO / RhD grouping
 - antibody screening















Haemagglutination













Mandatory/ discretionary testing

• Why do we test for what we do test for?

• Why don't we test for everything?







Mandatory screening			
Hepatitis B virus	HBsAg, (+HBV DNA)		
Hepatitis C virus	Anti-HCV, HCV RNA		
HIV	Anti-HIV I & II (+HIV Ag, HIV RNA)		
HTLV	Anti-HTLV I & II		
Syphilis	Anti-treponemes (inc other endemic infections)		
?HEV	?NAT		
Discretionary tests			
Hepatitis B virus	Anti-HBc, anti-HBs*		
Malaria	Anti-malaria		
T. cruzi	Anti- <i>T. cruzi</i>		
West Nile virus	Stopped 2006 (deferral in season). Restarted 2012		





Malaria Distribution







Vector of Chagas' Disease



Adult Rhodnius prolixus, a kissing bug. WHO/TDR/Stammers





Donor Infection Rates

HCV	1:12150
HBV	1:20500
HTLV	1:30750
Syphilis	1:32200
HIV	1:65000





Latex microparticles



Washed through to filter

INHS

 Assay specific acridinium-labelled antibody (or antigen) conjugate added to reaction well









Scientific and clinical Nucleic Acid Amplification Technology (NAT)







Residual risks for NHSBT (blood) donations

Risk due to	HBV	HCV	HIV
Window period donation			
No. (per million) entering the blood supply	0.46	0.026	0.17
1 per X million donations	2.2	39	5.9





Contaminated Platelets







•Bacterial Screening – 7 Day Platelets



